Learn About ALK-Positive Non-Small Cell Lung Cancer
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Stanford Health Care
Heather Wakelee is an Oncologist in Stanford, California. Dr. Wakelee is rated as an Elite provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Thymic Epithelial Tumor, Thymectomy, and Tissue Biopsy.
Duke Cancer Center
Jeffrey Crawford is a Hematologist Oncology specialist and a Hematologist in Durham, North Carolina. Dr. Crawford is rated as a Distinguished provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. His top areas of expertise are Small Cell Lung Cancer (SCLC), Squamous Cell Lung Carcinoma, Lung Adenocarcinoma, and ALK-Positive Non-Small Cell Lung Cancer. Dr. Crawford is currently accepting new patients.
New York University
Joshua Sabari is a Hematologist Oncology specialist and an Oncologist in New York, New York. Dr. Sabari is rated as a Distinguished provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Tissue Biopsy, and Thrombectomy.
Summary: This phase I trial is studying the safety, side effects, and best dose of gilteritinib in treating patients with stage IV ALK positive non-small cell lung cancer (NSCLC) who have progressed on other treatments. While there are many approved targeted drugs for ALK NSCLC, resistance to these drugs frequently occur. Giltertinib is a drug that is already FDA approved for the treatment of a specific ty...
Summary: This is a study of brigatinib in adults with Non-Small Cell Lung Cancer (NSCLC). The main aim of this study is to learn about the time period in which the condition does not worsen after the participant has received brigatinib. Another aim is to learn about the overall rate of participants who respond to the treatment with brigatinib. Participants will receive brigatinib as part of their normal cl...